Aurinia Pharmaceuticals (AUPH) 10 May 222022 Q1 Earnings call transcript

Greetings, and welcome to the Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in a listen-only mode and a question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Dana Lynch, Aurinia's Senior Director of Corporate Communications and Corporate Affairs. Thank you. begin. may you Dana,

and to all XXXX discuss James, call financial joining and webcast Aurinia's thank you, for you today's results. Thank first quarter

CEO; Chief Officer, morning, Officer, this of Miller, we of our of a the also Form Chief the me be morning Medical quarterly specifically, Peter will the and members remarks President the our call. Joining Max Q&A the report Dr. This team, recent and announcing Colao, Solomons, available release are call. Other Chief prepared Officer; portion will who and and operational Financial executive be Commercial leading Greenleaf, Joe issued for press conclusion on results filed at financial XX-Q. highlights Neil our

our Exchange Securities to on the For also available please filings Commission, website are more and at www.auriniapharma.com. our refer U.S. which with information,

make actual on a subject call, statements our and significant this current During of materially. are number forward-looking will statements These to expectations. results differ we may uncertainties, forward-looking and based our risks

a in filings available XXXX, no and Securities Authorities. note statements. otherwise obligation currently and at unless affect Canadian business, with us the any Exchange XX, as noted such Form XX-K statements assume information that today, made all of of along to during future our and based of refer please this financial Securities by to May Please as U.S. results law, disclosures and to XX-Q, For that required current today's call time. are press quarterly are our we Except update upon report factors our our with on and release the all recent our could and discussion Commission

Peter? over me Peter turn President the Now Aurinia's CEO, to please let call and Greenleaf.

joining Dana. Thanks thanks to today. for us on call everyone the And

reinforce the And call including provide in that, for and the regulatory update we will on trends patients. the update clinical the Europe and a our Joe I’ll for business on before finally today’s more our performance the the quarter. expenses are for first the provide gain After and as I’ll efforts we second with over Miller as our results, work provide position LUPKYNIS on-going move commercial our through positive to in a quarter to quick company. additional review of who on the I’ll seeing For a agenda, start LUPKYNIS update handing R&D LUPKYNIS brief to pipeline cash a benefits overall position then and QX financial detailed approval

some off get our let’s quarter, of to So on, early net in business in In XXXX. Inspite on $XX.X a we’ve started great we performance. challenges start sales. first first quarter million generated the

patients. in starting forms year-end a As appointments prescriptions patients and in discussed of in schedule. slowdown refilling late COVID-XX our Many impact on on in we on prescribers December unable arrays a call faced experienced many and patient physician were the attend given February, start to normalized

down and commercial resets As at year, converting our copay new is patients slow forms and considerable see get year coverage began in existing and it calendar the new of the patients and employer start typical patient the new the carriers trends covered to insurance of a improvements in for often timing encouraging Exiting start industry, policies we changes to quarter on affect within takes treatment, though, the patients year. our to results.

rates in high since the and XXXX a March the XXXX. the of total now patient start added significantly. Friday, level year. Conversion XX% March, prescription XXX we prescription forms the drug a the launch. XX, at refill robust quarter in rates May start XXX at of monthly at XX-days. of in form record highest Patient patient new as start compared of start patient to as And first improvements year, after since we and the conversion ending access stand increased are for First, fact, also quarter rates. start we well clear X remain since the in With upturn notable as forms are now prescribing start to XXX In forms has experienced for as recorded

On access have encouraged Through early, LUPKYNIS patient And confirmed access plans of are in approximately the to six we patients persistence representing XX% lives. while therapy of total still on trends. of through about XX% remaining months front, we're payers U.S. treatment. by

balanced regular and remain adoption prescribers, remains adding repeat provider rates we're and care consistent both prescribing health Each prescribers number increase to of new and rheumatologists in nephrologist. month of positive. practice efforts between the Additionally, LUPKYNIS growing

level Beyond increase three we've recent and care drug. and seen of is you providers. the if the the since surveys unaided health most equation awareness and XX% represents highest among XX% awareness to benefits next months its important brand branded on launch LUPKYNIS prescribing in over the over which of intend add XX%, now to use awareness over in significant Based is

trends, above time. per our go year. to and therapy therapy approximately progressive patients on at on more there previously, initial expect these as per guidance of Net stay this at on March were XXXX. approach revenue XXX realizable remains of we've on the discussed patient LUPKYNIS with compared we XXXX end patients over But XX,XXX as Given XX figure per therapy XXXX patients patient

there with directly are to interact to to normalize, conditions person care health more Finally, patients. we're with opportunities providers, in report happy continuing that with and

commercial Our are ramping activities accordingly. up

commercial Spring since across first Aurinia with our boost Kidney the medical last sales advocacy Just from representatives teams National meetings with our marketing, the Foundation attended medical Clinical Boston. affairs and lost meeting in-person in LUPKYNIS we attending month, first

share set patient awareness and educate patient data has begun further care Additionally, provider program. and to health of extensive of roll to including launched on new initiation and a number programs a initiatives, develop X and LUPKYNIS of AURORA ambassador marketing engagement an out we focused

and sales $XXX full million reaffirm for continued and our confident LUPKYNIS $XXX return remain care our guidance practices in plans United the for of execution, With normal health commercial million net expanded to XXXX. the year we the for to States of

we label, on As licensing the recovery have to our agreements of sales a European on the does to up in or payments, in European guidance use voclosporin potentially the the Otsuka without the If Union Medicines any in potential manufacturing cost well reminder, low half milestone as of anticipated to to and revenue, we plus approved second royalties voclosporin XXXX, Japan. and receive related depending royalty favourability Agency with supply Otsuka. $XX as not for double to million digit include our or the a arrangement approved have is cost sales ex-U.S. market

process. the We continue to work closely support approval with Otsuka to European

X efficacy X XXXX. posed of at Renal on will the in Rheumatology which reinforces time study sites in Congress a of year believe XXXX. XXth patients more European XXXX next original by given second peer an track work, reviewed and and safety This a document regard manuscript XXX the the trial. complete for comparable is for ENLIGHT-LN the the risk to our associations scientific into R&D additional at the received in continuing June. three study Congress. the well throughout results patients continuation the as treatment. months a plan both XXXX study will followed new approval submissions from first for XX at REGISTRY the We on-going interactions day XX pre-EMA publication over Data conferences EMA AURORA XXXX be pediatric abstract European fronts, second XX-month as European of by have up week voclosporin reported December seen research and continuing. was we Association we half On to data of for major With with looked we additional of question recruitment AURORA AURORA presentations to from initial in study, and of period in still the half We favorable vocal for submit we and the remain rheumatology other present of benefit the Alliance from a This that presentation at X LUPKYNIS profile this

committed knowledge a taking access initiated help well care about vocal And to to and we the as finally, patients FDA REGISTRY we LUPKYNIS, part we to our their continue both therapy. for gain study patient As to and track in improve to as XXXX. a the and further XXX build-out approval, of while the payers reminder, clinicians to both our of in as for term work build next Aurinia. enabling remain AURXXX, compounds on submit we to INDs and pipeline AURORA and for growth long advance These value steps IND are important ensure sustainable

at contribution, are least positioned significant the million our turn may we continued market current Joe while With LUPKYNIS years of weakness peers to quarter with our well relative the we answer our or for call in few As and and said fund U.S. a no operations and Joe? overall balance questions will healthy through many more then biotech flexible economy the of and now and remain a recap business have. return for I'll over $XXX the financial revenue approximately Miller at the of for detailed sheet review obligations. weathering previously, a can biopharma end the the hand, results. debt next on I the to call the in I any you company

everyone. Thank Peter morning and you, good

activities, for post to XXXX. payments activities, we few and million primarily investments March and and had respectively. The current resources in $XXX.X plan for commitments, the include at million million equivalents compared XX, investing research the $XXX,XXX $XXX.X we operations, receipts commercial by of funding the and XXXX, to of of the made our for a years. cash investment partially LUPKYNIS. believe is payments one $XX.X XX, commercial including approval infrastructure, on-going packaging offset and of December adequate XXXX continued and revenue the programs, payment obligations XX, cash As forecasted drug which approval fund and related financial XXXX, and in R&D Total conducting commercialization cash, restricted XX, FDA to and that sufficient development was least our supply, from time demand, ended at March decrease and pipeline, our sale ensure supply March manufacturing, meet funding associated related with cash XX, next achievement operating to have our of and March commercial pipeline, to XXXX purchases We supporting of advancement quarters post increase inventory activities an milestone, for

sales for XXXX. expenses as at LUPKYNIS. and were XX, adjustments January product late which due The of to in period. general were fixed and XX% administrative as and of XX, March of million revenues XXXX cost sales LUPKYNIS, the due were costs for completed lower fully due approximately March March March March were of XXXX. ended quarter LUPKYNIS. Total XXXX cost and Quarter-over-quarter and tied XXXX, $XX.X was in the million commercialization attributed various follows: to respectively. was XXXX for to fluctuation the net in following a LUPKYNIS AURXXX expenses quarters to decrease during is the was million, increase for XX%, quarterly matters, primarily the the AURXXX Cost the XX, to to in launch quarter partially the in revenue consistent XX, These our million related in pharmacovigilance overall to $XX.X related be expenses, continuation specialty and quarter in increase of professional Gross an prior study quarter-over-quarter and development, primarily $X.X gross and burdened offset Non-cash cost $X March XXXX not the was AURORA operating XXXX primarily quarters a first was driver by a in $XX,XXX costs XX, X for XX, percentage million consulting related percentage quarter was in SG&A is infrastructure January of primary expenses prior comparison The volumes expenses progress first the fluctuation $X.X late of Sales million to related due XXXX XX, margin have in XXXX. XX, comparison which expenses an XX, The XXXX XXXX in XXXX and and March the share-based sales the wind the million XX, ended on-going a investment company's and $X.X XX, consisted ended Selling, March approval $XX.X revenue for fourth increase further March the employee FDA quarter sales. growth compared increased but into respectively. to XXXX approval margins with of Our sales fees $XX.X is were support of R&D share-based respectively. the of primarily of March respectively. expenses of and and XXXX increase by can XXXX XXXX million higher for the as The expense for until ended as XXXX. the quarter represents costs quarter related corporate XX, quarters XXXX to ended and million $XXX,XXX had launch. quarter activities March March SG&A broken back driven pharmacy and the XX, to office was and million, $X March of compensation to down of Non-cash R&D of respectively. the compensation growth ended the to The of down expense ended increase $XX.X quarters overall

for or XXXX. common share net hand of to quarter as or XX, For Aurinia the compared back Peter closing that, the remarks net XXXX, the like share, loss net $XX.X $X.XX $XX.X net million quarter call a I'd recorded ended With for March per a March here.Peter? loss loss loss XX, to over common million per ended $X.XX of to

address heard healthcare and LUPKYNIS, and Thanks, provider the diagnosis result will patients seen experience to call, excited number as treatment nephritis optimistic trends comfort which patients of are and the lupus months. The in providers of prescribing in recent providing And a health urgent we signals their condition. Joe. we've early, treating care and you we're therefore more the throughout increases in with improving therapy with on the by continuing

in closer two commercial novel in for Beyond IND as submission quickly AURXXX the moving moving results, as towards triggering milestones, approval U.S. the and our to acids, AURXXX. potential possible well Europe, additional we’re

We you taking items With enable as strategy. with updating on And to a long will to which questions. year operate have sheet look continue on your us we the term balance our for today. to all healthy forward forward execute progresses. that. That's these to Look

the operator it Q&A. Let me to turn for

Joseph come Securities. Thank question from to today Our ahead. you. at first Schwartz Instructions] go [Operator is SVB Please going

today. thank Hi, the all for you this questions Congrats your recent is Bill progress. taking on for Joe, and on

So you company the one us, does here with IPR? when has on-going remind filed how response should Sun its an unfold? expect just for and this Thank we litigation update And kind can on of us you. the process pharmaceuticals? to And the

over Okay, thanks. coming sorry And Leerink, that SVB team was Joe choppy a Schwartz in. at little

any litigation, to So updates to actually the IPR and to submitted process, everybody on submitted repeat for question let and me the on IPR the Sun related pharmaceutical U.S. we response the the call. It Sun Trade Patent the on have by our Office.

that news Sun start on that XXXX So we where for we The for believe voclosporin's infringes upon have update to that sometime with in that probably ophthalmic that the litigation ophthalmic is Pharma We're litigation, infringement there's most solution. is us no on-going. patent there. are is CEQUA suing patents really we'll recent solution our product the our calling Sun for their litigation

until So for no any wouldn't XXXX. Joe, new news look there, and

response [Ph] in review alongside back late three June. believe, response. On so our then date the PTAC the response, IPR has, them recognize the our to months to I the filing application, so And process, the initial the patent officially, for of office is

year, back of So in for late look nothing early I it the would the call something XQ half in but XQ, new. the

get not submitted until as to the our it. yet we're latter have June of of still We in. part And submission have we that because response formulating

you. Great, thank

you, Mr. Schwartz. Thank

line at the Fitzgerald. going next to Cantor is from of come Our question Olivia Brayer

far. recommend questions. can as big for it's maybe the between forward? that an capital adoption one of some help the early good that may launch, the on then versus versus still Hi, follow days should willingness guys. a from XQ? insurance seasonality like going up And are between rheumatologist initially so in drag I forward. things more got the headwind allocation. more other? the us of you and And have uptake but potential on factors thanks a around seeing do Joe, one morning, impacts, And And know Omicron I going two out for play how of then different one about you be that the you some guys drive sense to can we did there is seeing anything drove impact think give nephrologist group I've you changes, similar How on the

Colao we too, right Let rheumatologist with get Max here me as and you detail, said in me almost on on into down nephrologist me middle. start now, terms can the this call between is of prescribing let but right so is deeper the and our split

first. a we lies is intensity caveat the want emphasis we Lupus therein I between importance rheumatology. specialties, a earlier as to that the them both is put a there there's higher go on think so diagnosis, and albeit, patient rheumatologist patient to that that So, And and we the caveat against value that increase needs equally obviously, diagnosis,

on-going of seasonality of terms consideration. In sort

take So it I'll Max. turn then give I'll and my over to

on specialty a think insurance much co-pays. rare pharma in some into at of reset I every start company see time other think, any I as to to a change to period who reset. as January, face COVID, products you enter employers bulk February look that you're you as others being year, plans, specialty and January, the things that, have can impact out like going go-forward basis, like have barring patients we equation, and large patients, And of of

mentioned we're you start the launch and TBD would accordingly, add? what January year early and be be job Max there guidance, whether into QX and annual every beyond, the looks to same the our I move distributing of give on the sort we As has because in you've in overall ramp patients while the our, some done analyst should think give impact where and you exactly don't we will quarterly think a I good base of out year guidance is as PSFs

saw would also, was as there impact Yes. I the for on just above refill on thanks care a to and had just and general impact And January February, the able of of in therapy. What your an to that insurance. just question. patients add Peter Thanks, rates, reset we beginning of highlighted beginning that is, what January, beyond and being continue is

we the were And in completely rheumatologist patients up and just was that in look is record fact, saw and back that And we normalize it's of we between And that I QX. rates we that's to would nephrologist. refill what a actually three And forms, balanced where so where add opened as over the we both things physician we've they March go March. as month And specialties. start on a across saw terms intensive in balanced in see XX%. but right prescribing completely highlighted, in intensity at seen treat, front is when prescribing month reflected then

had question? you Olivia, another

Brayer, you And you operator. star If Miss I Brayer the is Thank the could, re lost with your line is from queue one could this I and invite we've once open you, Miss presently. signal to again.

you guys Hey, hear me can now?

ma'am. Yes,

great. M&A guys. front, have obviously a guys the Okay, position. on nice you cash Thanks, then And

much stage And wholly term? whether doing So near asset, can sense a a adding of it's maybe you level that versus of, owned have deal us some give a is with willingness of more there de-risking. is a interest, a do mid to development more you'd strategic partnership where

a But and of our our strategy. we've part continuous in we part as think, it's and said, I of company firmly as diversification mission innovation, historically, believe

AURXXX XXX is in we that and business So through key deals as development XXXX. evidenced did both the to that,

sense deals market, a these going for So valuations it to fact are even [Indiscernible]. partnership that are we obviously a one assets, are, But which but healthy it's I'll to done. how now, opportunity together. difficult indications higher not companies not, where we cash attractive, come get they as I we have We important, there's raising balance deals that, just our want i.e. is, of And assets, right right are push we the M&A the is try the as current more for get no all of position of done. think everything to but and to larger money and urgency licensing sheet, licensing the not size, emphasize to out magic programs, there, are significant we're represents are not, from becoming of of things

only order asset company in fact, value of or priority, a prefer and and thought company. the something the likely itself we of out to the most we'd were, the is intrinsic yes, program So in over we of acquiring that critical acquire the individually, a We success the if had company towards license couldn't company. company to capabilities a leverage

clear, it front. keep progress you nothing steering and globalization but priority, is priority business one our launch away that. So, everybody's U.S. from but of on number the development sure is our LUPKYNIS LUPKYNIS posted on We’ll making and head

Got it. Thanks very much.

Brayer. Thank you, Miss

Our Jeffries. next Raycroft, Maury Dr. today question line is line the your at from open. will come of Raycroft

good Congrats thanks progress on questions. my and Hi, morning. taking for the

see. Let's

can your So is or patient Are just related point? you other to there can if XQ these transient update? you provide Or insights on discontinuations managing the you this any the that wondering how patient? elaborate explanations in or at issues mentioned doctor compliance are

Yes, I’m to on that join Max to conversation. me ask going

of months be January, at across crossed more the the we a of lighter. And launched healthy of six we months think is of have it's because the therapy. therapy would we're data XX of patients seeing since months number number have I patients Obviously, of six end who board. answer my providing of

XX% we Max, be But so forward, the go to on give views of why term we'll might you as So or longer any a to want patients as product to start gestures. that. color give

that point I'll that, Maury. more Sure, seen the at we've a months, commenting consistent here. for thanks XX% six couple which for discontinuation And quarters that is before now question, make one

kind that on this that, rates. talked the was primary the then about the it's what And, and and And patients discontinuation consistent temporary some we one beyond the what as I discontinuing discontinuation issues just in the is expect really, just of there make as patients just of one outside up show tolerability start, there's that was see reasons we say you terms a refill that discontinue. will was that there I'll a those treatment. for that reasons the the rebounded. that's saw more which point fourth we I just early So really quarter as discontinuation in the the patients in now that discontinuation, reasons And would with of typical would of for there that impact in noted, was was and quarter. beginning was above that Maury,

it. Got

Okay.

And therapy, come so presumably, or? outside could tolerability, is these onto way or of safety of back some the the right that patients it, actually to think about

We've others but on seen patient, I just patients products. doctor their cycle high, again. be taking says Proteinuria products is off analog it's not, sees therapy even explain finally the doctor, your tracking a that to your do one still that in way it's therapy taking MMF stops would start do, like and not patients And think guidelines, and of

don't your we to that importance medication patient, on keep pertains have So driven saying And itself, can’t come us a it's they've seen reasons something control. back. not come see getting to was all in these the back, not education they you coming on to and and product, like on patient, heard, and they're to And medication we'll that Proteinuria decisions. focus non-responder patient overtime. of Lot our are educating under the the we're considered this to an increase the and your we patient's on of back an as stay once continue disease have

about really what with talk and are? Got helpful you're your if just perspective. then metrics pricing And more you seeing it. what can latest That's wondering assumptions

we're average this in said, Well, first as at XX,XXX at, of per year giving net we the year around net or patient. an per launch

thing been plug in you one then the XX%. ability, is thing to morning then that been because quarter, to haven't drug number on believe specifics, Adherence, we're a says As sticking goes we that, we indicated why around it know the in migrate changes. do vary want is forward, average patient we above that once and really or that consistent has pretty given last to it's that net. and that we’ll we that that. towards And that's we do a at The continue carry

prescription, they're the thing on etcetera. on looking number of they're it. your at of if terms that's doses, good in monthly And a So average staying

said, private So, depending on safe XX. stage is pay, dosing a think versus average been data, more going all vary how land XX and much than on mix of we to At utilized as this But because EGFR insurance bet we've net adherence it's carrier, patients until overtime. just higher are have we public to has

Got it.

Okay. Makes sense. Thanks my for questions. taking

Maury. Thanks

Coming up Ku to at is Company. next the our follow -- question Stacy Cowen and

go line open. ahead. Your is Please

Hi, And thanks our for good the Congrats morning. on questions. quarter. taking

So additions. form comments and last patient start From that first, we seeing start math a really added XXX is patient your specific our forms from we're quarter, roughly March. in

we seeing the of And wanted cadence that be to are should March terms run so you the number? about So you thinking How Is That's in are just from question. are first you seeing Or growth in kind are patients far? of more what additions? seeing confirm that? the QX rate? the of a quarter-over-quarter that start What you form?

could you talk The second question is, repeat if about prescribers.

you. kind good, different What use or happy of of kind provide profile. kind getting figured they've of those planning those are questions. metrics they're to two what be around efficacy still those with waiting? the out that kind Thank of of that kind And to have willing are once how So clinics adopted with you’d versus

what number let we me that and just exact March, I'm in XXX. we count and is said honest What with March didn't had we with you I how she for give to told start Miller So our the but let was said make just eyes PSFs yet had sure me the know math. Joe don't

coming wasn't into the an that's of number. number of gave did That's, we bit little month average the when a end earnings. through the full high, kind we that February It year-end

at on run look you're high highest month overall, So monthly rates, bit our But today. of was you little kind March a March. as

that's And when then we Yes. And number, say consistently we quarter always but what end I tell Stacy earnings that you on what year-end growing in the see, to give number, most And growth. week. of note give can quarter-on-quarter What with that's then number were you noted, that where of reported. as then as quarter, see to call, want QX. far date number. is a about QX, we've to Friday is we ahead of And into the gave you it we growth, XXX. do you and want last was you saw the from would think to QX, what what I report year-to-date, on I right the dip, And you about we PSF is up It's we we'll which we'll you seeing and with on consistent of want this. representative the depending track where slight we the track that's give with we We'll done we're was growth be. QX QX so to over

habits of to just prescriber things for once a are couple here. And product for off terms of cover kind here, prescribers of they've and repeat the your In One, it. more question being yes used on just on let expedient apt prescribers me use this share Max.

from So repeat high and consistent. see we initial prescription strong secondary quite do and after so prescribing prescribing is

the our get, decile, over has the to a happy as But decile number share to grow breadth continued talking sales XX force as doc, upon with of to And per top depth quite we're that perspective, we've deployment based cases, we and times our into highest both but in our the as our drug we docs quarters what grow. prescribing in penetration continues of then more in to docs, the they once we'll next and top and of [ph] deciles, continue docs the of decile the of physicians after our and our some been our XX there then look to have, patients tier obviously, and the do. increase reusing what Second, couple to prescribers debts more the number our put are has like. our importantly, average penetration penetration patients to stuff and to apt our lower breadth more been small

It's that. very Thanks helpful. for

Ed will come today question Arce Please next HC go Our Wainwright. from ahead. at

hear my you questions. taking me? everyone. Hi, Thanks Can Okay. for

Sure can.

me. for questions Few Great.

any in release XX for My period mentioned conversion the the you describe the well, you question that us from rates for days. the is, the ask, up about provide of PSF average if to any could and wanted up. I there at year EU and Otsuka, lessons conversion, consistency, could potentially be would have split XX% milestones learned First, the treatment. consistent, therapy, learned does a I now And you experience in million that then with that now you over details any forth? keeping and you've year not lessons XX regarding persistence the then is average, terms obviously staying compliance, perspectives like? that just On required there, And could onto rates, far approval, later patients, to potential so this share? And labeling what refill follow from on the look what of work you to so then patients million, and but wondering on from lastly, as a PSF after had XX towards

lists, closer one those all through on as the The of down this million mind, on we because go my million and U.S. payment, we've match of historically. a from label, up is the to here's closer so a I'll Okay, label to $XX what XX comes duration how you comes last the we'll to come assured utilization. be first to of together the backwards ones the range $XX usually Otsuka, million said on the go

payment match color it lower. can product would all closer the to the So XX the would to on can is million assured be I you see. you be U.S., meaning number that for comes we be three closer the EMA XX. if were But can up the therapy give only the That's a to you know said the to months that the by used be six

And days far our any conversations in XXX both XXX [ph] we co-rafter showstoppers and conversations see here. in at the and so days don't and rafter with

and me I we than patients at input average, I asked good are think converting The I feel on rate, you conversion go then patients, TSF because plenty, Max's above, more we we should but you days, to specifically on drugs. color rate, give about to PSF are conversion XX and So [Indiscernible] it. our about there. there. let XX% want have of

give XX-day up than And almost drugs. which we days, was a more on XX you but XX number. XX%, number, are over XX, So to as a XX%

improving. we're quick, pretty off get they So

historically, a as we're over we want ones days. we're And XX that be. up track point said within at and at looking to I XX% I've mean, think we're days I possible. are want we're on where be to like, As XX-day we and we're not of XX But to want XX, them faster, and get XX XX, We on have as the almost is with many eight, XXX% looking perfection, at and to even now important pre-XX. converted to period getting at

physical quality Lastly, that just patients, indicator on patient symptoms, no I'll because And of no natural disease emphasize critical. presents that to stay patient lessons with there life a drugs. this learned forces signs and that with is on it's

you're the And biologic joints. we the hurt, disease joints kidneys Lupus helping arthritis, of is be to risk. because on of the impact quiet to therapy it's disease their stay we more healthcare it's need the lives your overall be themselves overly because the stay disease. progresses on If may at nephritis the to the need apt if shows educated and educated And be a for need potentially, data your because we on not. rheumatoid a to providers; therapy, their what patients until patients

So be are call you our patient Max? in investment patient education, mentioned increasing script, programs there, continuing support And the paramount. we're as

improved would have think and add, on would head, our the speed, that I add I what the mean, processing I hit what quarter. I every Yes, is Peter nail we

team put with really this regular significant to then helping physician conversion, investments ensure those support bearing converted basis. centers and and treatment. speeding up We put And stay management alliance as education, academic the we We in in key adherence also And are patient resources offices any is highlighted Peter are in patient’s population. or or on significant fruit more connects is a are on having of that patients resources forms start case patients rate significant that for than XX% fast. that

That's That's great. helpful. you. Thank

Just me. more up one for follow

You and patients. study underway the enrolling pediatric mentioned vocal

the wondering of much. down any Just could for line. us Thanks commitments, delineate coming what's post be so to just so up approval other if you aware

on mentioned, for previously Ed, everyone dear the as call. a reminder just Yes, and

and commitments been has data which vocal our application marketing part on-going. ongoing. lactation post study, the with study the which in and EMA, The is were pediatric there those AURORA the Our obviously, peds EMA. extension time. the is on on-going a then one; agency peds a of the study, interaction And X The over as out shared which lastly, and I think report been will on has And study one drug that is study lactation studies completed. was is

at and As been will submitted on I stage some and said, then a primarily obviously X submitted. submitted that the study been ped has disease this the I completed The effects take drug-to-drug interaction disease time this is vocal has aged AURORA believe a females. middle study fatal

a down that have younger getting we time. that. all belief the But So, will into take we do can audience

a support registry, investigator are the we that secondarily, therapy like environment. on and those So further of both in nature in invest understanding our world real that individual things ENLIGHT-LN continue and commitment said, to initiated level and with research studies to global study, the higher through the

so thanks much, Peter. Great,

Thanks, Ed.

Sahil of from hear we'll the Next, Dhingra at RBC. line

morning. Good

my they Thank elaborate from end on year question number the the to My on QX XXX have by is Good questions. Sahil Doug taking for of of therapy, XXXX quarter-on-quarter revenues? the Miehm. can patients in please I increased of for When first at morning, Hi, at end XXXX. this decline look you total you is, the

is it a function Can of is the up? comment on that? like refills? it is on patients you function that please you And driving have I then So a EGFR quarter-on-quarter? revenues lower Or more a follow have

question. understand sure I the not I'm

the that need you accumulated or more little says You're have to you're I are am Can about asking the grown? pointing that Gabi at patients it? patient, clarify I just net patient I sure a What understand? asking, price get per

and release, that of XXXX. the patients QX the were the there of at XXX in March press end So the at it XXXX, at of was XX at end mentioned end XXXX

net there but additions have declined. revenues to the So are patients,

Or is function reduction refills it QX? like I program? lower So anything are to it during it wanted of the dose is is it else? just there a understand, more is on patients Or

call, to you're net be not Yes, so you're right. as refill mentioned impact COVID that, prescriptions down. patients, refill patient with taking at to question the you rates Matt, one got it the the we and we changes as plan just you XXX due is up there grew you a patient mentioned, is that rates, would the growth number, straight we And quarter is, said, also while to have look as with And your if had what the XXX, lower. line, doing picking patients account not in insurer because now I and saying a you're were

this, down, due the to try up keep we'll number, quarter refill. net on primarily net the why in see in obviously, revenue to patient in we consistent but though because and we per even and So a revenue I increased we like partially the, then the went number think, this we hopefully the a next quarter dip quarter, that saw

refill patient. answer you for per rate the is based on simple So there

that… prior consistent the on And the dose patients are with reduction quarter. Is that

to as And Yes, there. I seen patients. happened we haven't anything significant on adjusting would dose any not dramatic yes, QX changes with look

we've Some clinical saw seen what around far our on so in consistent or pretty we at in practice the trials market.

more Earlier, on around rate, have which Okay, the that today is compliance months the the happens you And is to was discontinuation which on that XX%. mentioned question. three you commented months, around And rate, six is XX% that for I one drug XX%. have within have patient

of looking both should or is when them, So actually, deduct patients, it combined? we net at we're

data XX go-forward days. a basis for at happens of give did originally the we the you of that best we we've like No, XX% when where XX on give being not as discontinued months XX of data should you six On what we drug or at done was what six that persistency look months gave drug was we had at drug months who our patients we those is which remain in inclusive have number numbers one actually first days. on grouping get

not double So it's a hit.

my my end. much is clarifying from That questions. so all you for Thank Great.

you. Thank

Martin David Bloom from comes Burton. question at next our forward moving And

if my that Yes, go I'll Benlysta? been morning. doctors clients Or new back other in do and prescribing quarters. or they they in both good give also using decide they couple tend are prescribing which kindness but Benlysta? which yet are have any prescribing our one of decide asked, insight them to to a they're drugs, to the get as they of previous to Most to questions generally pick The patients

ability to past, the Yes, answer we've, are. just through LUPKYNIS for are, different than about of we pretty how there's CNIs. about almost they treatment also for think prior Benlysta talk listed nephrology, lupus. a the is we've break use thanks. to LUPKYNIS as LUPKYNIS with I manifestations in what positioning the of about them in stronger whether think think experience and Rheumatologist rheumatologist, we is, we've use a or question. have and their in which data the for with that And, Well, really types have tough and is this question comes Benlysta. to what general they with really Their consistent patient's we generation preference for Yes, Thanks from level also said they Proteinuria to on we've different what seen the a of patients. for when it's the position with state it. their really, the one me and lupus that with think is Benlysta, And they the when how that's health

nephritis as So patient lupus thing get it when use Benlysta is nephrology, when they the is were they new get keep patient use even and lupus a now. drug. the patient or when the right sometimes they getting on we the initiate And good us that sometimes to Benlysta they they lupus they has lupus nephritis, when selecting preferential nephritis a seems patients our rheumatologist then in to for lupus

keep how numbers you we'll on So posted moving forward. move those

nephritis, is then And fail? they on they first until are lupus waiting diagnosed newly the LUPKYNIS or with steroids doctors combination? before nothing put it them patients Okay, line

LUPKYNIS of Well, is to towards what in treatment said paradigm the is track and our tracking the I combination to time over start our receiving amount with the and appreciate, patients to MMF goal of greatest we've and steroids are change line But in you first. steroids patients be think on who as is are population success the majority patients these therapy. can as diagnosed going David, and that first MMF coming are in treated these

to in the seeing seen currently diagnosed the our So patients of or And we're the a predicted. are track of growth but we our equation a it's and end. steroids drug added and percentage newly course going is have to it patients, majority which smaller time, MMF over on is are as

achieve LUPKYNIS good of last and on? lowering a partial patients keeping a remission to the enough they Or if doctors on Okay, is Proteinuria them complete only question, remission? are just keep a

longitudinally it I'll from the don't give to we're know the I anecdotally Yes, track. we give of we to a docs. that Proteinuria sort rates hearing hear you Max on or what you what monthly pitch and only can we

to that what is coronary to from a Proteinuria. is hearing don't they're decreased goal get goal is XX% overall happy level down. to And response, reach and treatment. they're clearly, that Yes, certain they're decrease the stop looking in their they get we're Proteinuria and but The of for complete with a docs a that,

recall… and Okay,

In mix. stated most the to adding our cases drug they're

So you're care of benefit over standard getting majority an incremental the for the of current patients.

are that list. question. patients I And already of these layered When you top other lupus great. it their on do one say have i… adding seeing you Okay, the mix to being LUPKYNIS Are with on

B-cell yet approach. have hypothetically, in strategy that's practice now, right our that's strategy. be in could haven't We treatment an a our C&I thought least data. about in haven't combination and do about But as not one that we at seen We inhibition talked base not leader although whether talks with see that we a

Okay. That’s you. it. Got it. Thank

Thanks, David.

hear Kim now Oppenheimer. Justin we'll And at from

run a Maybe fourth pretty of quarterly through questions. and script thanks I'm number QX morning, prior up between estimate asking even on questions. the good Hi, suggest Stacy’s for our just the stable taking quarter a rate. follow to

to team change the And, those the for reach So just to look understand, of factors or maybe whether of what maybe or macro as to sort expects through Can of you maybe trying guidance. shift practices you numbers it's those high think changing physician not over numbers year? of sort the the prescriptions? like, end you or about us walk the with, micro that the how changing balance and script

at it's QX, When start it's say not, that prescription of QX, talking if think I total not are patients. slightly was it forms in produced at the like you were we Justin, it XXs look of prescription, dependence you XXX look a and slightly. number Well, I down patients, what

rate. at as are on we in directionally, run So growth a we don't least QX. back back over projections into again, but a QX, And we we're give PSS, quarterly in trajectory move

we where be, your So given we can math you do want on. own estimated that's to haven't probably but

are of prescription what If form like at you in carry an quarter six into figure back a months, the at look a in XX and to on XX% they honor an make right be. where what patients believe PSS you quarter attrition rate months growth and assumption start could our has

QX? the than You revenue pure has to retenant QX, are can be rate Because way also numbers the were in be. working rates obviously, could the bigger, rate if there form you growth numbers We standpoint, would we but are of to to what And All in we we're from QX. QX to can start is I where not we based on the tell have in improve continue we were QX on. order what want into prescription from is be achieve to numbers the where from where off retenant estimate a we them there. it about steady, held maybe improvements think

a and our seeing throughout entire year, prescription model the activity factor. growth one execution. that's form throughout grow that So around continued there opening, continued then not about QX. refills assumptions And It's our start in multiple

it. who any around patients kinase Okay, this the team have the is XXX XX-month several setting having Just observations reached updated on could Got how boarded time have in point? And being administered commercial or thinking does okay. this point? maybe beyond the

XX then had in like other biggest several XXX months. drug at way probably assumption going at over this all honesty, diseases the at report number that's, etcetera. to Yes, magical the business drug. are if numbers a at patients to when just to less is just the But would we you're But what think months. and what's question on to and what's natural mean, in we be benchmark time the XX. to at rare rather through biologics. that at be you're It's And, she going it patients through had less And I by fair that XX months, be the six than just be it and other going against is, it's before, XX probably back, way XX-month indications, months, I who that we'd me, matter at at XX say is. this, progress, that that our less that point, XX XX small that's months, a of will seen XX%, of and And the end have months it significant six the

believe and on and comment each It's you grows, we'll rate. it we consistent so give it that is say, So can't quarter generally be going to we continue outside it we speaking, have a we think declined projectable. end it which we just what that to report that so can at And sizable decline. when will just to something enough

responses with abstract of and reach renal into know of And date time one a can commercially what at just of as curious that one just falling any therapy observations some observed, question the to at populations sort of renal the observed of ERA, that curious squeeze at later time of taking being sort they the final to you duration look look kind at data around that patients there points that of those maybe if was or [Indiscernible] five, we response just taking later maybe a class if another? maybe sort you is, longer are, and is time mix on

renal you think prospectively, reason looks of track response what world time numbers. vocal Like actually doing in into that stepped I the so some those that like. real to can right we're study, the we

renal REGISTRY. give I the or ENLIGHT-LN to the So what can't you response time

think renal But I what in shows Dr. But vocal. said response. world can't you time I of evidence terms give Sorry, to I real

Solomon phone, the the is on probably question? give you bit the want you commentary can a specifically, Neil, you're give about heard more if on he any talking to abstract little

his you asking, it have that wasn't quickly to you was what response saying? touched compared proliferative around question. you're I Did any Yes, differential quite how sure the exactly information by were Was patients?

that is at So just among various duration is in various as just respond, longer around observed And more setting? in me…. the therapy, And whether disease are the to of are whether general severity times? severe and populations in disease as class trends there patients potentially maybe time term or observed and so and to any the different commercial

the XX% when example, mean, that. I around us at child doing it. you a who presented, of wealth that's child about in, play. the see been said Peter for so what patients and workers abstracts, reason yes, AURORA to in think many of I the a And data the also only should And going registry five. is real things or course, went give look has at the of world, But information there's we're and I the the

of at populations kind of patients. look relatively small we So

have it'll enough point. It'll more we we registry. cuts more obvious and think as fill like our own become become just I and this don't in knowledge more do at

So I at have mean, yeah, all this we that's point.

Thanks. Understood.

for everyone joining want for I call to us today. thank so Alright, the

that time concludes a good with day. think the I that our question, have earnings. QX and for you last Thank

Aurinia Ladies today's quarter Pharmaceuticals and results and does call. conclude gentlemen, operational financial this first XXXX conference

and your disconnect rest day. enjoy You lines now the of that we you hope may your